Simultaneous Pharmacokinetic Model for Rolofylline and both M1-trans and M1-cis Metabolites
Journal Title: The AAPS Journal - Year 2013, Vol 15, Issue 2
Abstract
The online version of this article (doi:10.1208/s12248-012-9443-5) contains supplementary material, which is available to authorized users.
Authors and Affiliations
Mark Stroh, Matthew M. Hutmacher, Jianmei Pang, Ryan Lutz, Hiroshi Magara, Julie Stone
Keywords
Related Articles
- EP ID EP681101
- DOI 10.1208/s12248-012-9443-5
- Views 74
- Downloads 0
Utilizing Internal Standard Responses to Assess Risk on Reporting Bioanalytical Results from Hemolyzed Samples
Bioanalytical analysis of toxicokinetic and pharmacokinetic samples is an integral part of small molecule drugs development and liquid chromatography—tandem mass spectrometry (LC-MS/MS) has been the technique of...
Summary Workshop Report: Facilitating Oral Product Development and Reducing Regulatory Burden Through Novel Approaches to Assess Bioavailability/Bioequivalence
This summary workshop report highlights presentations and over-arching themes from an October 2011 workshop. Discussions focused on best practices in the application of biopharmaceutics in oral drug product development a...
Receptor-targeted gene delivery viafolate-conjugated polyethylenimine
A novel synthetic gene transfer vector was evaluated for tumor cell-specific targeted gene delivery. The folate receptor is a tumor marker overexpressed in more than 90% of ovarian carcinomas and large percentages of oth...
Concepts and Challenges in Quantitative Pharmacology and Model-Based Drug Development
Model-based drug development (MBDD) has been recognized as a concept to improve the efficiency of drug development. The acceptance of MBDD from regulatory agencies, industry, and academia has been growing, yet today...
Blood pressure as an example of a biomarker that functions as a surrogate
There are many important uses of biomarkers in drug development. An area of particular interest is the use of biomarkers as surrogate end points. Only a small minority of biomarkers are established surrogate end points....